The transcription factor, Bright and immunoglobulin heavy chain expression

Immunologic Research

Volumn 24, Issue 2, 2001, Pages 149-161

  Webb, C F ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Bright; Bruton's Tyrosine Kinase; Chromatin; Immunodeficiency Disease; Immunoglobulin Transcription; Nuclear Matrix

Indexed keywords

ANTIGEN; BRUTON TYROSINE KINASE; IMMUNOGLOBULIN HEAVY CHAIN; NUCLEAR PROTEIN; PROTEIN LYSP100B; PROTEIN SP100; PROTEIN TYROSINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BRIGHT; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; AT RICH SEQUENCE; B LYMPHOCYTE ACTIVATION; CELL NUCLEUS MATRIX; CHROMATIN STRUCTURE; IMMUNE DEFICIENCY; IMMUNOGLOBULIN PRODUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN FAMILY; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; X CHROMOSOME LINKED DISORDER;

DNA-BINDING PROTEINS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; NUCLEAR MATRIX; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; PROTEIN-TYROSINE KINASES; TRANS-ACTIVATORS; UP-REGULATION;

EID: 0034836386     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1385/IR:24:2:149     Document Type: Article

References (77)

1. Transcription factors required for lymphoid lineage commitment
2. Transcription factors controlling B-cell development
3. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement
4. Functional immunoglobulin transgenes guide ordered B-cell differentiation in Rag-l-deficient mice
5. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death
6. Impaired expansion of mouse B cell progenitors lacking Btk
7. Defective B cell development and function in Btk-deficient mice
8. Immunodeficiency in protein kinase Cβ-deficient mice
9. Requirement for B cell linker protein (BLNK) in B cell development
10. BLNK: Connecting Syk and Btk to calcium signals
11. Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement
12. Targeted disruption of the Oct-2 locus in a B cell provides genetic evidence for two distinct cell type-specific pathways of octamer element-mediated gene activation
13. Oct-2, although not required for early B-cell development, is critical for later B-cell maturation and for postnatal survival
14. The B-cell-specific transcription coactivator OCA-B/OBF-1/Bob-1 is essential for normal production of immunoglobulin isotypes
15. B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal centre formation
16. The transcriptional promoter regulates hypermutation of the antibody heavy chain locus
17. Expression of Bright at two distinct stages of B lymphocyte development
18. Induction of immunoglobulin μ mRNA in a B cell transfectant stimulated with interleukin-5 and a T-dependent antigen
19. Novel protein-DNA interactions associated with increased immunoglobulin transcription in response to antigen plus interleukin-5
20. The immunoglobulin heavy-chain matrix-associating regions are bound by Bright: A B cell-specific trans-activator that describes a new DNA-binding protein family
21. An upstream Oct-1 and Oct-2 binding silencer governs B29 (Igβ) gene expression
22. Regulation of matrix attachment region-dependent, lymphocyte-restricted transcription through differential localization within promyelocytic leukemia nuclear bodies
23. Cux/CDP homeoprotein is a component of NF-μNR and represses the immunoglobulin heavy chain intronic enhancer by antagonizing the Bright transcription activator
24. Differential regulation of immunoglobulin gene transcription via nuclear matrix-associated regions
25. Characterization of the dead ringer gene identifies a novel, highly conserved family of sequence-specific DNA-binding proteins
26. The human dead ringer bright homolog, DRIL1: cDNA cloning, gene structure, and mapping to D19S886, a marker on 19p13.3 that is strictly linked to the Peutz-Jeghers syndrome
27. Bdp, a new member of a family of DNA-binding proteins, associates with the retinoblastoma gene product
28. Solution structure of the DNA binding domain from dead ringer, a sequence-specific AT-rich interaction domain (ARID)
29. Identification of a matrix-associated region 5′ of an immunoglobulin heavy chain variable region gene
30. Chromosomal loop organtization in eukaryotic genomes
31. Expression of the (recombinant) endogenous immunoglobulin heavy-chain locus requires the intronic matrix attachment regions
32. Dependence of enhancer-mediated transcription of the immunoglobulin μ gene on nuclear matrix attachment regions
33. Extension of chromatin accessibility by nuclear matrix attachment regions
34. V(D)J recombination in B cells is impaired but not blocked by targeted deletion of the immunoglobulin heavy chain intron enhancer
35. Recombination and transcription of the endogenous Ig heavy chain locus is effected by the Ig heavy chain intronic enhancer core region in the absence of the matrix attachment regions
36. MARs of antigen receptor and coreceptor genes
37. A topoisomerase II-like protein is part of an inducible DNA-binding protein complex that binds 5′ of an immunoglobulin promoter
38. A developmental-specific factor binds to supressor sites flanking the immunoglobulin heavy-chain enhancer
39. LYSP100-associated nuclear domains (LANDs): Description of a new class of subnuclear structures and their relationship to PML nuclear bodies
40. The retinoblastoma gene family in differentiation and development
41. The transcription factor Bright associates with Bruton's tyrosine kinase, the defective protein in immunodeficiency disease
42. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia
43. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases
44. X-linked agammaglobulinemia: New approaches to old questions based on the identification of the defective gene
45. Mutations in Btk in patients with presumed X-linked agammaglobulinemia
46. Mutation of the unique region of Bruton's tyrosine kinase in immunodeficient XID mice
47. Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes
48. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages
49. Mutation of the pleckstrin homology domain of B ruton's tyrosine kinase in immunodeficiency impaired inositol 1,3,4,5-tetrakisphosphate binding capacity
50. Characterization of the pleckstrin homology domain of Btk as an inositol polyphosphate and phosphoinositide binding domain
51. Structure of the PH domain and btk motif from Bruton's tyrosine kinase: Molecular explanations for X-linked agammaglobulinaemia
52. The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C
53. Binding of beta gamma subunits of heterotrimeric G proteins to the PH domain of Bruton tyrosine kinase
54. BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement
55. The SH3 domain of Bruton's tyrosine kinase interacts with Vav, Sam68 and EWS
56. Binding of Bruton's tyrosine kinase to Fyn, Lyn, or Hck through a Src homology 3 domain-mediated interaction
57. An SH3-binding site conserved in Bruton's tyrosine kinase and related tyrosine kinases mediates specific protein interactions in vitro and in vivo
58. Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells
59. IL-5 receptor-mediated tyrosine phosphorylation of SH2/SH3-containing proteins and activation of Bruton's tyrosine and Janus 2 kinases
60. Missense mutations affecting a conserved cysteine pair in the TH domain of Btk
61. Nucleocytoplasmic shuttling of Bruton's tyrosine kinase
62. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization
63. Cloning of an Inr- and E-boxbinding protein, TFII-I, that interacts physically and functionally with USF1
64. An alternative pathway for transcription initiation involving TFII-I
65. TFII is required for transcription of the naturally TATA-less but initiator-containing VBeta promoter
66. TFII-I regulates Vβ promoter activity through an initiator element
67. Regulation of TFII-I activity by phosphorylation
68. H promoters in vitro
69. Family-specific differences in transcription efficiency of Ig heavy-chain promoters
70. Immunologic memory to phosphocholine VII. Lack of T15V1 gene utilization in Xid anti-PC hybridomas
71. The CBA/N mouse strain: An experimental model illustrating the influence of the x-chromosome on immunity
72. Immunoglobulin class switch recombination machinery: Progress and challenges
73. Cooperative interaction of an initiator-binding transcription initiation factor and the helix-loop-helix activator USF
74. TFII-I enhances activation of the c-fos promoter through interactions with upstream elements
75. Adapter proteins in lymphocyte antigen-receptor signaling
76. BTKbase, mutation data-base for X-linked agammaglobulinemia (XLA)
77. Mutation screening of the BTK gene in 56 families with X-linked agammaglobulinemia (XLA): 47 Unique mutations without correlation to clinical course